MGMT and glioblastoma: Some of these molecular genetic alterations, for example, isocitrate dehydrogenase 1 and 2 (IDH1/2) mutation and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, have been recognized as more appropriate diagnostic and prognostic markers, respectively, in GBM than histological appearance alone [11, 12].